Pheochromocytoma and paraganglioma (PPGL) · line 1 · I-131 MIBG radiopharmaceutical therapy (MIBG-avid metastatic pheochromocytoma/paraganglioma)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-IODINE-131-MIBG-PHEO |
| ID | IND-PHEO-METASTATIC-1L-MIBG |
|---|---|
| Type | Indication |
| Status | reviewed 2026-07-11 |
| Diseases | DIS-PHEOCHROMOCYTOMA |
| Sources | SRC-NCCN-NET-2025 |
Notes
Coverage-enabling metastatic-disease indication for DIS-PHEOCHROMOCYTOMA, MIBG-avid branch. No Test/Biomarker entity for "MIBG scan positive" exists in the KB as of this authoring pass -- MIBG avidity is instead expressed as a free-text decision-tree condition in ALGO-PHEO-1L (mirroring the existing free-text-condition pattern already used throughout ALGO-RCC-METASTATIC-1L). expected_outcomes fields are deliberately left qualitative/unquantified rather than populated with specific percentages the drafting agent cannot verify. Requires nuclear medicine / medical oncology co-lead signoff before clinical publication.
Used By
Algorithms
ALGO-PHEO-1L- ALGO-PHEO-1L
Disease
DIS-PHEOCHROMOCYTOMA- Pheochromocytoma and paraganglioma (PPGL)